Real-world treatment and outcomes of metastatic colorectal cancer patients with a poor or very poor performance status
- Author(s)
- Travers, A; Jalali, A; Begbie, S; Semira, C; Kosmider, S; Ananda, S; Wong, R; Lee, M; Shapiro, J; Burge, M; Yip, D; Torres, J; Ma, B; Nott, L; Dean, A; Tie, J; Khattak, A; Lim, S; Wong, HL; Gibbs, P;
- Journal Title
- Clinical Colorectal Cancer
- Publication Type
- Journal epub ahead of print
- Abstract
- BACKGROUND: The management of metastatic colorectal cancer patients with a poor performance status (PS) continues to be a clinical dilemma, with the potential activity and safety of treating this population remaining poorly understood. Few of these patients are enrolled onto clinical trials, and poor PS is often multifactorial. PATIENTS AND METHODS: We analyzed the Treatment of Recurrent and Advanced Colorectal Cancer registry to describe treatment practices and outcomes in poor (Eastern Cooperative Oncology Group [ECOG] PS 2) and very poor PS (ECOG PS > 2) patients to explore the relationship between age, tumor burden, comorbidities, and PS, and to evaluate the benefit of systemic therapy. Standard descriptive statistical methods, Kaplan-Meier analysis, and a multivariate Cox regression model were used. RESULTS: Of 2769 registry patients (diagnosed January 2009 to June 2018), 329 (12%) and 182 (7%) patients had a poor and very poor PS, respectively. Good PS patients were more likely to receive systemic therapy than poor and very poor PS patients (85%, 55%, and 21.5%, P < .0001), but clinician assessed response was observed in all subsets (53%, 41%, and 29%, P = .0003). Treatment with chemotherapy was associated with longer median overall survival across PS groups. Exploratory analysis based on comorbidity score and tumor burden subgroups demonstrated a consistently positive overall survival association with treatment. Benefit was observed where poor overall survival was attributable to medical comorbidities and to tumor burden. CONCLUSION: In routine clinical care, a substantial proportion of poor and very poor PS patients receive active treatment, which is often associated with meaningful clinical benefit.
- Publisher
- Elsevier
- Research Division(s)
- Personalised Oncology
- PubMed ID
- 32919889
- Publisher's Version
- https://doi.org/10.1016/j.clcc.2020.08.002
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2020-10-02 10:28:01
Last Modified: 2020-10-02 10:34:22